

21 May 2020

Malaysia Results Review

Consumer Non-cyclical | Rubber Products

Buy (Maintained)

Target Price (Return): MYR6.08 (32.5%) Price: MYR4.59 Market Cap: USD1.362m

Analyst

alan.lim@rhbgroup.com

Avg Daily Turnover (MYR/USD)




45.4m/10.2m

Alan Lim, CFA +603 9280 8890



Share Performance (%)

	YTD	1m	3m	6m	12m
Absolute	230.2	136.6	192.4	223.7	189.4
Relative	240.6	135.8	199.6	234.8	200.7
52-wk Price low	/high (MYF	₹)		1.30) – 4.59



Source: Bloomberg

Supermax Corp (SUCB MK)

Earnings Doubled, Best Is Yet To Come! Still BUY

• Still BUY with a higher DCF-derived MYR6.08 TP from MYR3.90, 33% upside and 1% yield. 3QFY20 (Jun) earnings more than doubled and beat expectations. Both sales and margins are at record highs. As we expect 4QFY20 earnings to do even better, we increase our earnings estimates and TP. Our new TP implies 28.6x FY21 forward P/E. This reflects a 20% discount against the sector's average forward P/E of 35.8x, which we believe is justified due to Supermax Corp's lower market cap/liquidity.

- Earnings beat expectations. 9MFY20 core net profit of MYR126m trumped expectations, as it makes up 79% and 86% of our and consensus' FY20 estimates. The outperformance was caused by exceptional sales and EBITDA margins registered in 3QFY20. Note that sales surged 16% QoQ (+24% YoY) to MYR447m due to a climb in gloves demand. EBITDA margins also expanded QoQ and YoY on declines in raw material prices.
- 3QFY20 core earnings more than doubled QoQ and YoY... In 3QFY20, Supermax's core net profit surged 105% YoY and 136% QoQ to MYR71m. The superb earnings are fundamentally driven. Note that both sales and EBITDA margins are at record highs for the company.
- ...and the best is yet to come! We expect 4QFY20 earnings to be better than 3QFY20. Note that the ASP increase effect has not been fully reflected in this period. We believe the ASP increase only started from mid-February onwards - up to end March - for 3QFY20. As the price increase trend has likely continued in April and May, 4QFY20 will reflect the full impact of ASP rises from April-June. See page 5 for our demand-supply analysis.
- · Higher magnitude of ASP increase against peers due to own brand manufacturing (OBM). While we expect the gloves industry's ASPs to increase, Supermax's magnitude should be higher. Note that 50% of its products are sold under the OBM segment, which allows it to enjoy margins all the way up to the end customer level instead of selling to distributors under the original equipment manufacturer (OEM) segment. Almost all of its peers' products are sold as OEM. After raising our ASP estimate, we have increased FY20F-22F earnings by 18-28%.
- BUY with a higher MYR6.08 TP. The higher TP is in line with better earnings estimates. In the near term, we expect Supermax to have an even stronger set of results in 4QFY20, which will capture a full quarter of higher ASPs. In the long run, Supermax is a beneficiary of the long-term uptrend in global gloves consumption: 8-10% annually, even without COVID-19. Risks to our call: Lower-than-expected sales volumes and USD/MYR, and higher-than-expected raw material prices.

Forecasts and Valuation	Jun-18	Jun-19	Jun-20F	Jun-21F	Jun-22F
Total turnover (MYRm)	1,304	1,538	1,708	2,035	2,204
Recurring net profit (MYRm)	107	123	196	278	325
Recurring net profit growth (%)	-	15.5	58.9	41.9	16.9
Recurring P/E (x)	56.22	48.67	30.63	21.58	18.47
P/B (x)	5.9	5.3	4.8	4.1	3.6
P/CF (x)	33.84	25.51	15.85	14.23	13.58
Dividend Yield (%)	1.7	0.3	1.1	1.6	1.9
EV/EBITDA (x)	24.98	25.97	17.96	12.97	10.94
Return on average equity (%)	-	11.5	16.4	20.4	20.7
Net debt to equity (%)	28.5	19.2	2.4	net cash	net cash

Source: Company data, RHB

Financial Exhibits

Asia
Malaysia
Consumer Non-cyclical
Supermax Corp
SUCB MK
Ruy

Valuation basis

We use DCF-FCFE valuation.

Key drivers

Our earnings forecasts are most sensitive to:
i. Nitrile and latex gloves volumes;
ii. USD/MYR;
iii. Raw material prices.

Key risks

Downside risks include:

- Lower-than-expected volumes;
- ii. Volatile currency movements;
 iii. Volatile raw material prices.

Company Profile

Supermax is one of the world's Big 4 glove makers. It produces both latex and nitrile gloves.

Financial summary (MYR)	Jun-18	Jun-19	Jun-20F	Jun-21F	Jun-22F
Recurring EPS	0.08	0.09	0.15	0.21	0.25
DPS	0.08	0.02	0.05	0.07	0.09
BVPS	0.78	0.86	0.97	1.12	1.29
Return on average equity (%)	-	11.5	16.4	20.4	20.7

Valuation metrics	Jun-18	Jun-19	Jun-20F	Jun-21F	Jun-22F
Recurring P/E (x)	56.22	48.67	30.63	21.58	18.47
P/B (x)	5.9	5.3	4.8	4.1	3.6
FCF Yield (%)	2.0	2.0	3.8	4.5	4.9
Dividend Yield (%)	1.7	0.3	1.1	1.6	1.9
EV/EBITDA (x)	24.98	25.97	17.96	12.97	10.94
EV/EBIT (x)	30.14	32.25	23.84	16.39	13.63

Income statement (MYRm)	Jun-18	Jun-19	Jun-20F	Jun-21F	Jun-22F
Total turnover	1,304	1,538	1,708	2,035	2,204
Gross profit	430	510	670	809	882
ЕВІТДА	244	232	325	434	497
Depreciation and amortisation	(42)	(45)	(80)	(91)	(98)
Operating profit	202	187	245	344	399
Net interest	(14)	(20)	(4)	1	6
Pre-tax profit	162	172	257	365	427
Taxation	(52)	(49)	(60)	(86)	(100)
Reported net profit	107	123	196	278	325
Recurring net profit	107	123	196	278	325

Cash flow (MYRm)	Jun-18	Jun-19	Jun-20F	Jun-21F	Jun-22F
Change in working capital	57	31	97	53	23
Cash flow from operations	177	235	378	421	442
Capex	(59)	(112)	(150)	(150)	(150)
Cash flow from investing activities	(55)	(112)	(143)	(138)	(134)
Dividends paid	(76)	(33)	(59)	(83)	(97)
Cash flow from financing activities	(126)	(104)	(27)	(61)	(135)
Cash at beginning of period	156	145	174	392	624
Net change in cash	(4)	19	208	222	173
Ending balance cash	145	174	392	624	806

Balance sheet (MYRm)	Jun-18	Jun-19	Jun-20F	Jun-21F	Jun-22F
Total cash and equivalents	145	174	392	624	806
Tangible fixed assets	900	969	1,018	1,068	1,121
Total investments	197	208	208	208	208
Total assets	1,700	1,843	2,096	2,423	2,674
Short-term debt	374	331	294	336	327
Total long-term debt	62	61	129	121	114
Total liabilities	677	708	824	954	977
Total equity	1,023	1,134	1,273	1,468	1,697
Total liabilities & equity	1,700	1,843	2,096	2,423	2,674

Key metrics	Jun-18	Jun-19	Jun-20F	Jun-21F	Jun-22F
Revenue growth (%)	0.0	17.9	11.0	19.2	8.3
Recurrent EPS growth (%)	0.0	15.5	58.9	41.9	16.9
Gross margin (%)	33.0	33.2	39.3	39.8	40.0
Operating EBITDA margin (%)	18.7	15.1	19.0	21.3	22.5
Net profit margin (%)	8.2	8.0	11.5	13.6	14.7
Capex/sales (%)	4.5	7.3	8.8	7.4	6.8
Interest cover (x)	14.5	9.5	21.2	32.1	40.3

Source: Company data, RHB




Figure 1: Results snapshot

FYE June (MYRm)	3QFY19	2QFY20	3QFY20	QoQ (%)	YoY (%)	9MFY19	9MFY20	YoY (%)	Comments
Revenue	361.2	385.5	447.2	16.0	23.8	1,113.4	1,202.7	8.0	Surge in gloves demand.
EBITDA	64.3	59.3	111.9	88.7	74.0	202.2	220.4	9.0	Higher margins due to high OBM
EBITDA margin (%)	17.8	15.4	25.0			18.2	18.3		exposure.
Depreciation	(10.4)	(12.8)	(13.1)	1.9	26.3	(32.0)	(38.5)	20.2	
EBIT	52.3	46.5	94.2	102.8	80.2	166.6	176.8	6.1	
EBIT margin (%)	14.5	12.1	12.1			15.0	14.7		
Interest expense	(4.5)	(4.6)	(3.5)	(23.7)	(22.3)	(13.8)	(12.3)	(10.7)	
Pre-tax profit	49.4	41.8	95.3	127.8	92.8	156.4	169.5	8.4	
Pre-tax margin (%)	13.7	10.9	21.3			14.0	14.1		
Tax	(14.5)	(11.8)	(22.9)	94.2	58.6	(46.8)	(42.2)	(9.7)	
Effective tax rate (%)	29.2	28.2	24.1			29.9	24.9		
Minority Interest	0.3	(0.1)	1.3	nm	nm	1.0	1.4	n.m	
Net profit	34.6	30.2	71.1	135.6	105.3	108.7	126.0	15.9	Beat expectations.
Net margin (%)	9.6	7.8	15.9			9.8	10.5		•
Core net profit	34.6	30.2	71.1	135.6	105.3	102.2	126.0	23.3	Excludes MYR6.5m in insurance claims in 1H19.
Core net margin (%)	9.6	7.8	15.9			9.2	10.5		Ciaiii ii II 13.

Source: Company data, RHB

Beneficiary of a higher USD/MYR in 3QFY20. A stronger USD during the January-March period has been positive for Supermax, as almost all of its sales are booked in USD – this translates into higher MYR revenue. This is much higher than its cost component, in which only 60% of its raw material costs are USD-denominated.

Figure 2: USD/MYR trend




Source: Bloomberg

Margins expanded, as raw material prices (nitrile butadiene and latex) declined QoQ. From USD895.00 per tonne as of end-Dec 2019, nitrile butadiene prices have dropped 32% QoQ to USD605.00 per tonne as of end-Mar 2020. We believe this was likely caused by the decline in crude oil prices. As a result, Supermax enjoyed lower raw material costs, as 50% of its products are nitrile gloves made from nitrile butadiene.

The remaining 50% consists of latex gloves, which are made from natural rubber. Note that natural rubber prices declined 9% during the January-March quarter. As a result, Supermax EBITDA margin expanded to 25% in 3QFY20, ie much better than 2QFY20 and 3QFY19's 15.4% and 17.8%.

Figure 3: Raw material costs declined during the January-March period



Source: Bloomberg



Industry lead times have increased to 10 months. Our industry channel checks reveal that lead times have increased significantly in the past one month. This is likely caused by a surge in demand of at least 50%, based on our estimates.

On supply side, the industry is only able to expand by a maximum of 10% in the next three months in a best case scenario. This was caused by the Movement Control Order, which has significantly slowed down construction of new manufacturing plants. As a result, this has caused lead times to increase to 10 months. This is a significant increase when compared to 3-4 months seen in April.

In short, the demand-supply dynamics have tightened up, with buyers willing to wait until Jan 2021 for orders to arrive. Under such market condition, an ASP rise is inevitable, and it will be across the board for all gloves companies, in our view.

Valuation. In our DCF valuation, we have increased FCFF assumptions in line with the better earnings prospects. This was driven by a higher ASP outlook. We have also lowered our WACC assumptions, as Beta for the stock has declined.

Our DCF-derived TP of MYR6.08 reflects a forward P/E of 28.6x. While this is higher than its peak of 24.4x, we believe this is justified, as the counter is still at a 20% discount against its peers' average. Supermax also has a higher ASP increase potential due to the 50% product exposure to the OBM segment.

Figure 4: DCF valuation

Enterprise value (MYR m)

Equity value (MYR m)

Number of shares (m)

8.224

218

(473)

7,970

1309.90

6.08

FYE Dec (MYR m)	FY21F	FY22F	FY23F	FY24F	FY25F	FY26F	FY27F	FY28F	FY29F	FY30F	Terminal
CFO	421	442	421	489	529	541	581	622	649	668	
+ Interest (1 - tax rate)	(8)	(8)	(7)	(6)	(6)	(5)	(4)	(4)	(3)	(3)	
- capital expenditure	(150)	(150)	(150)	(150)	(150)	(150)	(150)	(150)	(150)	(150)	
Free cash flow to firm (FCFF)	263	284	265	333	373	386	426	468	495	515	13,486
Discount factor	0.92	0.85	0.78	0.72	0.66	0.61	0.56	0.51	0.47	0.44	0.44
PV of FCFF	242	241	206	239	246	234	238	241	235	224	5,877
Risk-free	4.0%	-									
Beta	0.81										
Cost of Equity	8.8%							•			
WACC	8.0%										
Terminal growth	4.0%										

TP (MYR)
Source: RHB

Cash

- Debt



Figure 5: Sector demand-supply estimates

Pieces (m)	2017	2018	2019	2020F	2021F
Hartalega	30,000	33,000	36,600	40,100	44,100
Growth (%)	39.5%	10.0%	10.9%	9.6%	10.0%
Kossan	22,000	26,500	29,000	32,000	35,000
Growth (%)	0.0%	20.5%	9.4%	10.3%	9.4%
Top Glove	51,600	60,500	70,100	76,000	84,000
Growth (%)	15.7%	17.2%	15.9%	8.4%	10.5%
Supermax	23,400	22,000	21,700	25,700	27,700
Growth (%)	10.9%	(6.0%)	(1.4%)	18.4%	7.8%
Sri Trang Gloves (Thailand)	21,000	21,000	25,000	27,000	30,000
Growth (%)	NA	NA	19.0%	8.0%	11.1%
Estimated capacity	148,001	163,000	182,401	200,800	220,800
Supply growth	13.7%	10.1%	11.9%	10.1%	10.0%
Demand growth	8.6%	7.9%	8-10%	15-18%	8-10%

- Our capacity supply assumptions may be less aggressive than glove producers' plans
- Our key assumption: Rational capacity expansion, in which producers will balance between volume growth and margins

Source: Bloomberg

Recommendation Chart



Source:	RHB,	Bloomberg

Date	Recommendation	Target Price	Price
2020-05-13	Buy	3.90	3.60
2020-03-15	Buy	1.86	1.71
2020-02-26	Buy	1.86	1.70
2020-01-23	Buy	1.86	1.52
2019-11-29	Neutral	1.50	1.34
2019-09-03	Neutral	1.61	1.46
2019-07-19	Buy	1.88	1.62
2019-05-15	Buy	1.88	1.57
2019-02-13	Buy	1.85	1.61

Source: RHB, Bloomberg

RHB Guide to Investment Ratings

Buy: Share price may exceed 10% over the next 12 months

Trading Buy: Share price may exceed 15% over the next 3 months, however longer-

term outlook remains uncertain

Neutral: Share price may fall within the range of +/- 10% over the next

12 months

Take Profit: Target price has been attained. Look to accumulate at lower levels Sell: Share price may fall by more than 10% over the next 12 months

Not Rated: Stock is not within regular research coverage

Investment Research Disclaimers

RHB has issued this report for information purposes only. This report is intended for circulation amongst RHB and its affiliates' clients generally or such persons as may be deemed eligible by RHB to receive this report and does not have regard to the specific investment objectives, financial situation and the particular needs of any specific person who may receive this report. This report is not intended, and should not under any circumstances be construed as, an offer or a solicitation of an offer to buy or sell the securities referred to herein or any related financial instruments.

This report may further consist of, whether in whole or in part, summaries, research, compilations, extracts or analysis that has been prepared by RHB's strategic, joint venture and/or business partners. No representation or warranty (express or implied) is given as to the accuracy or completeness of such information and accordingly investors should make their own informed decisions before relying on the same.

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to the applicable laws or regulations. By accepting this report, the recipient hereof (i) represents and warrants that it is lawfully able to receive this document under the laws and regulations of the jurisdiction in which it is located or other applicable laws and (ii) acknowledges and agrees to be bound by the limitations contained herein. Any failure to comply with these limitations may constitute a violation of applicable laws.

All the information contained herein is based upon publicly available information and has been obtained from sources that RHB believes to be reliable and correct at the time of issue of this report. However, such sources have not been independently verified by RHB and/or its affiliates and this report does not purport to contain all information that a prospective investor may require. The opinions expressed herein are RHB's present opinions only and are subject to change without prior notice. RHB is not under any obligation to update or keep current the information and opinions expressed herein or to provide the recipient with access to any additional information. Consequently, RHB does not guarantee, represent or warrant, expressly or impliedly, as to the adequacy, accuracy, reliability, fairness or completeness of the information and opinion contained in this report. Neither RHB (including its officers, directors, associates, connected parties, and/or employees) nor does any of its agents accept any liability for any direct, indirect or consequential losses, loss of profits and/or damages that may arise from the use or reliance of this research report and/or further communications given in relation to this report. Any such responsibility or liability is hereby expressly disclaimed.

Whilst every effort is made to ensure that statement of facts made in this report are accurate, all estimates, projections, forecasts, expressions of opinion and other subjective judgments contained in this report are based on assumptions considered to be reasonable and must not be construed as a representation that the matters referred to therein will occur. Different assumptions by RHB or any other source may yield substantially different results and recommendations contained on one type of research product may differ from recommendations contained in other types of research. The performance of currencies may affect the value of, or income from, the securities or any other financial instruments referenced in this report. Holders of depositary receipts backed by the securities discussed in this report assume currency risk. Past performance is not a guide to future performance. Income from investments may fluctuate. The price or value of the investments to which this report relates, either directly or indirectly, may fall or rise against the interest of investors.

This report does not purport to be comprehensive or to contain all the information that a prospective investor may need in order to make an investment decision. The recipient of this report is making its own independent assessment and decisions regarding any securities or financial instruments referenced herein. Any investment discussed or recommended in this report may be unsuitable for an investor depending on the investor's specific investment objectives and financial position. The material in this report is general information intended for recipients who understand the risks of investing in financial instruments. This report does not take into account whether an investment or course of action and any associated risks are suitable for the recipient. Any recommendations contained in this report must therefore not be relied upon as investment advice based on the recipient's personal circumstances. Investors should make their own independent evaluation of the information contained herein, consider their own investment objective, financial situation and particular needs and seek their own financial, business, legal, tax and other advice regarding the appropriateness of investing in any securities or the investment strategies discussed or recommended in this report.

This report may contain forward-looking statements which are often but not always identified by the use of words such as "believe", "estimate", "intend" and "expect" and statements that an event or result "may", "will" or "might" occur or be achieved and other similar expressions. Such forward-looking statements are based on assumptions made and information currently available to RHB and are subject to known and

unknown risks, uncertainties and other factors which may cause the actual results, performance or achievement to be materially different from any future results, performance or achievement, expressed or implied by such forward-looking statements. Caution should be taken with respect to such statements and recipients of this report should not place undue reliance on any such forward-looking statements. RHB expressly disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or circumstances after the date of this publication or to reflect the occurrence of unanticipated events.

The use of any website to access this report electronically is done at the recipient's own risk, and it is the recipient's sole responsibility to take precautions to ensure that it is free from viruses or other items of a destructive nature. This report may also provide the addresses of, or contain hyperlinks to, websites. RHB takes no responsibility for the content contained therein. Such addresses or hyperlinks (including addresses or hyperlinks to RHB own website material) are provided solely for the recipient's convenience. The information and the content of the linked site do not in any way form part of this report. Accessing such website or following such link through the report or RHB website shall be at the recipient's own risk.

This report may contain information obtained from third parties. Third party content providers do not guarantee the accuracy, completeness, timeliness or availability of any information and are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, or for the results obtained from the use of such content. Third party content providers give no express or implied warranties, including, but not limited to, any warranties of merchantability or fitness for a particular purpose or use. Third party content providers shall not be liable for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or profits and opportunity costs) in connection with any use of their content.

The research analysts responsible for the production of this report hereby certifies that the views expressed herein accurately and exclusively reflect his or her personal views and opinions about any and all of the issuers or securities analysed in this report and were prepared independently and autonomously. The research analysts that authored this report are precluded by RHB in all circumstances from trading in the securities or other financial instruments referenced in the report, or from having an interest in the company(ies) that they cover.

The contents of this report is strictly confidential and may not be copied, reproduced, published, distributed, transmitted or passed, in whole or in part, to any other person without the prior express written consent of RHB and/or its affiliates. This report has been delivered to RHB and its affiliates' clients for information purposes only and upon the express understanding that such parties will use it only for the purposes set forth above. By electing to view or accepting a copy of this report, the recipients have agreed that they will not print, copy, videotape, record, hyperlink, download, or otherwise attempt to reproduce or re-transmit (in any form including hard copy or electronic distribution format) the contents of this report. RHB and/or its affiliates accepts no liability whatsoever for the actions of third parties in this respect.

The contents of this report are subject to copyright. Please refer to Restrictions on Distribution below for information regarding the distributors of this report. Recipients must not reproduce or disseminate any content or findings of this report without the express permission of RHB and the distributors.

The securities mentioned in this publication may not be eligible for sale in some states or countries or certain categories of investors. The recipient of this report should have regard to the laws of the recipient's place of domicile when contemplating transactions in the securities or other financial instruments referred to herein. The securities discussed in this report may not have been registered in such jurisdiction. Without prejudice to the foregoing, the recipient is to note that additional disclaimers, warnings or qualifications may apply based on geographical location of the person or entity receiving this report.

The term "RHB" shall denote, where appropriate, the relevant entity distributing or disseminating the report in the particular jurisdiction referenced below, or, in every other case, RHB Investment Bank Berhad and its affiliates, subsidiaries and related companies.

RESTRICTIONS ON DISTRIBUTION

Malaysia

This report is issued and distributed in Malaysia by RHB Investment Bank Berhad ("RHBIB"). The views and opinions in this report are our own as of the date hereof and is subject to change. If the Financial Services and Markets Act of the United Kingdom or the rules of the Financial Conduct Authority apply to a recipient, our obligations owed to such recipient therein are unaffected. RHBIB has no obligation to update its opinion or the information in this report.

Thailand

This report is issued and distributed in the Kingdom of Thailand by RHB Securities (Thailand) PCL, a licensed securities company that is authorised by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is a member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. RHB Securities (Thailand) PCL does not endorse, confirm nor certify the result of the Corporate Governance Report of Thai Listed Companies.



This report is issued and distributed in Indonesia by PT RHB Sekuritas Indonesia. This research does not constitute an offering document and it should not be construed as an offer of securities in Indonesia. Any securities offered or sold, directly or indirectly, in Indonesia or to any Indonesian citizen or corporation (wherever located) or to any Indonesian resident in a manner which constitutes a public offering under Indonesian laws and regulations must comply with the prevailing indonesian laws and regulations.

This report is issued and distributed in Singapore by RHB Securities Singapore Pte Ltd which is a holder of a capital markets services licence and an exempt financial adviser regulated by the Monetary Authority of Singapore. RHB Securities Singapore Pte Ltd may distribute reports produced by its respective foreign entities, affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations. Where the report is distributed in Singapore to a person who is not an Accredited Investor, Expert Investor or an Institutional Investor, RHB Securities Singapore Pte Ltd accepts legal responsibility for the contents of the report to such persons only to the extent required by law. Singapore recipients should contact RHB Securities Singapore Pte Ltd in respect of any matter arising from or in connection with the report.

Hong Kona

This report is distributed in Hong Kong by RHB Securities Hong Kong Limited (興業僑豐證券有限公司) (CE No.: ADU220) ("RHBSHK") which is licensed in Hong Kong by the Securities and Futures Commission for Type 1 (dealing in securities). Any investors wishing to purchase or otherwise deal in the securities covered in this report should contact RHBSHK. RHBSHK is a wholly owned subsidiary of RHB Hong Kong Limited; for the purposes of disclosure under the Hong Kong jurisdiction herein, please note that RHB Hong Kong Limited with its affiliates (including but not limited to RHBSHK) will collectively be referred to as "RHBHK." RHBHK conducts a full-service, integrated investment banking, asset management, and brokerage business. RHBHK does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this research report. Investors should consider this report as only a single factor in making their investment decision. Importantly, please see the company-specific regulatory disclosures below for compliance with specific rules and regulations under the Hong Kong jurisdiction. Other than company-specific disclosures relating to RHBHK, this research report is based on current public information that we consider reliable, but we do not represent it is accurate or complete, and it should not be relied on as such.

United States

This report was prepared by RHB and is being distributed solely and directly to "major" U.S. institutional investors as defined under, and pursuant to, the requirements of Rule 15a-6 under the U.S. Securities and Exchange Act of 1934, as amended (the "Exchange Act"). Accordingly, access to this report via Bursa Marketplace or any other Electronic Services Provider is not intended for any party other than "major" US institutional investors, nor shall be deemed as solicitation by RHB in any manner. RHB is not registered as a broker-dealer in the United States and does not offer brokerage services to U.S. persons. Any order for the purchase or sale of the securities discussed herein that are listed on Bursa Malaysia Securities Berhad must be placed with and through Auerbach Grayson ("AG"). Any order for the purchase or sale of all other securities discussed herein must be placed with and through such other registered U.S. broker-dealer as appointed by RHB from time to time as required by the Exchange Act Rule 15a-6. This report is confidential and not intended for distribution to, or use by, persons other than the recipient and its employees, agents and advisors, as applicable. Additionally, where research is distributed via Electronic Service Provider, the analysts whose names appear in this report are not registered or qualified as research analysts in the United States and are not associated persons of Auerbach Grayson AG or such other registered U.S. broker-dealer as appointed by RHB from time to time and therefore may not be subject to any applicable restrictions under Financial Industry Regulatory Authority ("FINRA") rules on communications with a subject company, public appearances and personal trading. Investing in any non-U.S. securities or related financial instruments discussed in this research report may present certain risks. The securities of non-U.S. issuers may not be registered with, or be subject to the regulations of, the U.S. Securities and Exchange Commission. Information on non-U.S. securities or related financial instruments may be limited. Foreign companies may not be subject to audit and reporting standards and regulatory requirements comparable to those in the United States. The financial instruments discussed in this report may not be suitable for all investors. Transactions in foreign markets may be subject to regulations that differ from or offer less protection than those in the United States.

DISCLOSURE OF CONFLICTS OF INTEREST

RHB Investment Bank Berhad, its subsidiaries (including its regional offices) and associated companies, ("RHBIB Group") form a diversified financial group, undertaking various investment banking activities which include, amongst others, underwriting, securities trading, market making and corporate finance advisory.

As a result of the same, in the ordinary course of its business, any member of the RHBIB Group, may, from time to time, have business relationships with or hold positions in the securities (including capital market products) or perform and/or solicit investment, advisory or other services from any of the subject company(ies) covered

While the RHBIB Group will ensure that there are sufficient information barriers and internal controls in place where necessary, to prevent/manage any conflicts of interest to ensure the independence of this report, investors should also be aware that such

conflict of interest may exist in view of the investment banking activities undertaken by the RHBIB Group as mentioned above and should exercise their own judgement before making any investment decisions.

Malaysia

Save as disclosed in the following link RHB Research conflict disclosures – May 2020 and to the best of our knowledge, RHBIB hereby declares that:

1. RHBIB does not have a financial interest in the securities or other capital market

- products of the subject company(ies) covered in this report.
- RHBIB is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
- None of RHBIB's staff or associated person serve as a director or board member*
- of the subject company(ies) covered in this report
 *For the avoidance of doubt, the confirmation is only limited to the staff of research department
- RHBIB did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- RHBIB did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Save as disclosed in the following link RHB Research conflict disclosures – May 2020 and to the best of our knowledge, RHB Securities (Thailand) PCL hereby declares that:

- RHB Securities (Thailand) PCL does not have a financial interest in the securities
- or other capital market products of the subject company(ies) covered in this report. RHB Securities (Thailand) PCL is not a market maker in the securities or capital
- market products of the subject company(ies) covered in this report.

 None of RHB Securities (Thailand) PCL's staff or associated person serve as a director or board member* of the subject company(ies) covered in this report
- *For the avoidance of doubt, the confirmation is only limited to the staff of research department
- RHB Securities (Thailand) PCL did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months
- RHB Securities (Thailand) PCL did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report.

Save as disclosed in the following link RHB Research conflict disclosures - May 2020 and to the best of our knowledge, PT RHB Sekuritas Indonesia hereby declares that:

- PT RHB Sekuritas Indonesia and its investment analysts, does not have any interest in the securities of the subject company(ies) covered in this report.

 For the avoidance of doubt, interest in securities include the following:

 a) Holding directly or indirectly, individually or jointly own/hold securities or entitled for dividends, interest or proceeds from the sale or exercise of the
 - subject company's securities covered in this report*;
 - Being bound by an agreement to purchase securities or has the right to transfer the securities or has the right to pre subscribe the securities*
 - Being bound or required to buy the remaining securities that are not subscribed/placed out pursuant to an Initial Public Offering*.

 Managing or jointly with other parties managing such parties as referred to in
 - (a), (b) or (c) above.
- PT RHB Sekuritas Indonesia is not a market maker in the securities or capital market products of the subject company(ies) covered in this report.
- None of PT RHB Sekuritas Indonesia's staff** or associated person serve as a director or board member* of the subject company(ies) covered in this report.
- PT RHB Sekuritas Indonesia did not receive compensation for investment banking or corporate finance services from the subject company in the past 12 months.
- PT RHB Sekuritas Indonesia** did not receive compensation or benefit (including gift and special cost arrangement e.g. company/issuer-sponsored and paid trip) in relation to the production of this report:

*The overall disclosure is limited to information pertaining to PT RHB Sekuritas Indonesia only

*The disclosure is limited to Research staff of PT RHB Sekuritas Indonesia only.

Save as disclosed in the following link RHB Research conflict disclosures - May 2020 and to the best of our knowledge, RHB Securities Singapore Pte Ltd hereby declares

- RHB Securities Singapore Pte Ltd, its subsidiaries and/or associated companies
- do not make a market in any issuer covered in this report.

 RHB Securities Singapore Pte Ltd, its subsidiaries and/or its associated companies and its analysts do not have a financial interest (including a shareholding of 1% or more) in the issuer covered in this report.
- RHB Securities, its staff or connected persons do not serve on the board or trustee positions of the issuer covered in this report.
- RHB Securities Singapore Pte Ltd, its subsidiaries and/or its associated companies do not have and have not within the last 12 months had any corporate finance advisory relationship with the issuer covered in this report or any other relationship that may create a potential conflict of interest.
- RHB Securities Singapore Pte Ltd, or person associated or connected to it do not have any interest in the acquisition or disposal of, the securities, specified securities based derivatives contracts or units in a collective investment scheme covered in this report.



RHB Securities Singapore Pte Ltd and its analysts do not receive any compensation or benefit in connection with the production of this research report or recommendation.

Analyst Certification

The analyst(s) who prepared this report, and their associates hereby, certify that:
(1) they do not have any financial interest in the securities or other capital market products of the subject companies mentioned in this report, except for:

Analyst	Company
-	-

(2) no part of his or her compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report.



KUALA LUMPUR

RHB Investment Bank Bhd

Level 3A, Tower One, RHB Centre Jalan Tun Razak Kuala Lumpur 50400 Malaysia

Tel: +603 9280 8888 Fax: +603 9200 2216

HONG KONG

RHB Securities Hong Kong Ltd.

12th Floor, World-Wide House 19 Des Voeux Road Central Hong Kong

Tel: +852 2525 1118 Fax: +852 2810 0908

JAKARTA

PT RHB Sekuritas Indonesia

Revenue Tower, 11th Floor, District 8 - SCBD

Jl. Jendral Sudirman Kav 52-53 Jakarta 12190

Indonesia Tel: +6221 509 39 888 Fax: +6221 509 39 777

BANGKOK

Thailand

RHB Securities (Thailand) PCL

10th Floor, Sathorn Square Office Tower 98, North Sathorn Road, Silom Bangrak, Bangkok 10500

Tel: +66 2088 9999 Fax:+66 2088 9799

SINGAPORE

RHB Securities Singapore Pte Ltd.

10 Collyer Quay #09-08 Ocean Financial Centre

Singapore 049315 Tel: +65 6533 1818 Fax: +65 6532 6211